Non-valvular atrial fibrillation
Conditions
Interventions
Edoxaban monotherapy Edoxaban will be orally administered at a dose of 30 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 30 mg if the CLcr is 15-50 mL/min and at a dose
Sponsors
Nihon university school of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with non-valvular atrial fibrillation complicated with stable coronary artery disease who are 20 years or more at the obtaining of informed consent, CHADS2 score are 1 or more, and fulfil the criteria below and can provide written consent for participation in the present study will be eligible. 1) Patients who underwent percutaneous coronary intervention, including plain old balloon angioplasty, at least six months ago 2) Patients who have coronary stenosis requiring no percutaneous coronary intervention (50% or more stenosis) as indicated by coronary CT or coronary angiography 3) Patients who underwent coronary artery bypass graft CABG at least six months ago
Exclusion criteria
Exclusion criteria: 1)Patients who are contraindicated for edoxaban 2)Patients who are contraindicated for clopidogrel 3)Patients who are going to undergo revascularization 4)Those who are going to undergo invasive surgery (excluding digestive endoscopy and biopsy) 5)Patients who have active tumors 6)Patients who have poorly-controlled hypertension (systolic blood pressure at hospital admission: 160 mmHg or more) 7)Patients judged as inappropriate for this study by investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| major bleeding Clinically relevant non-major bleeding | — |
Countries
Japan
Contacts
Public ContactDaisuke Fukamachi
Nihon university school of medicine department of cardiology
Outcome results
None listed